Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Deferred Tax Assets (2016)

Enanta Pharmaceuticals filings provide 3 years of Current Deferred Tax Assets readings, the most recent being $1.1 million for Q2 2016.

  • On a quarterly basis, Current Deferred Tax Assets fell 34.72% to $1.1 million in Q2 2016 year-over-year; TTM through Jun 2016 was $1.1 million, a 34.72% decrease, with the full-year FY2015 number at $1.4 million, down 86.99% from a year prior.
  • Current Deferred Tax Assets hit $1.1 million in Q2 2016 for Enanta Pharmaceuticals, down from $1.6 million in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $11.2 million in Q2 2014 to a low of $1.1 million in Q2 2016.
  • Median Current Deferred Tax Assets over the past 3 years was $1.6 million (2015), compared with a mean of $3.6 million.
  • The widest YoY moves for Current Deferred Tax Assets: up 17.28% in 2015, down 86.99% in 2015.
  • Enanta Pharmaceuticals' Current Deferred Tax Assets stood at $1.3 million in 2014, then rose by 17.28% to $1.6 million in 2015, then fell by 27.45% to $1.1 million in 2016.
  • The last three reported values for Current Deferred Tax Assets were $1.1 million (Q2 2016), $1.6 million (Q1 2016), and $1.6 million (Q4 2015) per Business Quant data.